Wells Fargo Report Links GLP-1 Surge to 30% Bariatric Surgery Decline
0h ago|5 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
glp-1bariatric-surgery
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. AiX is informational software — not investment advice. Past performance does not guarantee future results.
A new report from Wells Fargo & Company highlights a significant shift in weight management treatment, linking the rapid adoption of GLP-1 drugs to a steep decline in bariatric surgical procedures. Robin Wenzel, Head of Wells Fargo Industry Insights, stated that the rise of these pharmaceuticals has reduced the rate of bariatric surgery by more than 30%, creating a less invasive alternative. Wenzel's analysis, reported by Bloomberg, also notes that GLP-1 use surged by 120% between 2022 and 2024, prompting a strategic pivot for healthcare providers. This pharmaceutical trend coincides with trading activity for Wells Fargo stock, which was priced at $83.70, down 4.23% on the day, as of 20:19 UTC today.
The trend identified by Wells Fargo represents a pivotal moment in the treatment of obesity and related metabolic conditions. The last comparable disruption in this therapeutic area was the approval and adoption of laparoscopic techniques in the 1990s, which made bariatric surgery significantly safer and more accessible. Today's macro backdrop of high healthcare costs and a focus on preventative care creates a receptive environment for non-surgical interventions that promise long-term cost savings. The primary catalyst for this shift is the recent clinical validation and subsequent insurance coverage expansion for GLP-1 agonists like semaglutide and tirzepatide, proving their efficacy in achieving sustained weight loss.
The change was triggered by a sequence of events starting with landmark clinical trial results published in 2021 that demonstrated unprecedented weight loss percentages. This was followed by updated guidelines from medical associations and, crucially, decisions by major insurers to cover these drugs for weight management, vastly expanding the addressable market. The current economic climate, with the US 10-year Treasury yield hovering around 4.3%, pressures healthcare systems to seek cost-effective solutions, making a pharmaceutical approach increasingly attractive compared to a costly surgical procedure with associated hospital stays. The report suggests the healthcare industry is now adapting to this new paradigm in real-time.
The core data from the Wells Fargo report reveals a stark inverse relationship between drug adoption and surgical volumes. The specific metric of a greater than 30% decline in bariatric surgery procedures is directly tied to the 120% growth in GLP-1 usage over the two-year period from 2022 to 2024. This shift represents a fundamental change in patient pathways for severe obesity. For context, bariatric surgery volumes had been growing at a steady compound annual growth rate of approximately 5-7% in the years preceding the widespread availability of these new drugs.
The financial implications are substantial. A single bariatric surgery can cost between $15,000 and $25,000, while annual GLP-1 medication costs can range from $12,000 to $16,000. The long-term cost-benefit analysis for payers is complex, weighing the one-time high cost of surgery against potentially decades of pharmaceutical expense. The market capitalization of leading GLP-1 manufacturers, such as Novo Nordisk and Eli Lilly, has soared into the hundreds of billions of dollars, reflecting investor anticipation of sustained demand. Meanwhile, medical device companies focused on bariatric surgery, like Johnson & Johnson and Medtronic, face potential headwinds to a segment that previously offered stable growth.
| Metric | Pre-GLP-1 Surge (Pre-2022) | Current (2024) | Change |
|---|---|---|---|
| Bariatric Surgery Growth | ~6% CAGR | >-30% | Negative inflection |
| GLP-1 Prescription Volume | Baseline | +120% | Massive adoption |
Wells Fargo's own stock, trading under the ticker WFC, reflects broader market movements, with its price at $83.70 after touching a daily range of $83.62 to $85.67.
This transition creates clear winners and losers across the healthcare sector. Pharmaceutical companies with successful GLP-1 portfolios, namely Novo Nordisk (NVO) and Eli Lilly (LLY), are the direct beneficiaries, seeing expanded revenue streams and dominant market positioning. Conversely, medical technology firms specializing in surgical instruments and equipment for bariatric procedures face a deteriorating growth outlook. Companies like Johnson & Johnson (JNJ) and Medtronic (MDT), which have sizable surgical businesses, may need to adjust forecasts for their respective divisions. The analysis suggests a re-rating of equities is underway, with capital flowing out of surgical device makers and into pharmaceutical innovators.
A key counter-argument to the bearish thesis for device makers is the possibility that GLP-1 drugs will serve as a bridge to surgery for some patients, rather than a replacement, by helping them achieve a safer pre-operative weight. the long-term adherence and real-world efficacy of these drugs outside clinical trials remain uncertain, posing a risk to the pharmaceutical growth story. Investor positioning appears to be heavily long the drug manufacturers, with short interest building in small to mid-cap pure-play medical device companies most exposed to bariatrics. The Wells Fargo report itself underscores this shift, framing the situation as an opportunity for parts of the healthcare industry to pivot toward managing medication regimens and side effects.
The immediate catalyst for market movement will be the next quarterly earnings reports from key players. Investors should monitor Eli Lilly's earnings on October 24 and Novo Nordisk's report on November 1 for updated prescription trends and revenue guidance for their GLP-1 franchises. For medical device companies, scrutiny will fall on commentary regarding procedure volume forecasts during their upcoming earnings calls. The next major clinical data readout to watch is the full results from the SELECT cardiovascular outcomes trial, expected in Q4 2024, which could further solidify the drugs' value proposition to payers.
From a market perspective, key levels to watch for WFC include the $80 support level, a breach of which could signal continued negative sentiment, and resistance near its 52-week high around $95. For the pharmaceutical leaders, investors will watch for any breakout above current all-time highs or a failure to hold key moving averages like the 50-day EMA. Regulatory announcements from the FDA regarding label expansions or from the Centers for Medicare & Medicaid Services regarding coverage policies will be critical inflection points that could accelerate or decelerate the identified trend.
GLP-1 receptor agonists are a class of medications initially developed for managing type 2 diabetes that have proven highly effective for chronic weight management. They work by mimicking a natural hormone that regulates appetite and insulin secretion. Drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have shown an ability to help patients lose 15% or more of their body weight, positioning them as powerful alternatives to invasive surgery. Their use requires a prescription and is typically intended for long-term management of obesity.
The cost structure differs significantly. Bariatric surgery involves a large one-time cost, typically $15,000 to $25,000, covering the procedure, hospital stay, and immediate follow-up. GLP-1 drug therapy involves a recurring annual cost, often between $12,000 and $16,000 for the medication alone. While the first-year drug cost may be lower, the long-term financial impact over five or ten years can exceed the one-time surgical cost, creating a complex calculation for health insurers and patients regarding the most cost-effective solution over a lifetime.
The most directly affected public companies are the GLP-1 manufacturers Novo Nordisk (NVO) and Eli Lilly (LLY), which are experiencing massive revenue growth. On the opposite side, medical device companies that derive significant revenue from bariatric surgery instruments and supplies, such as Johnson & Johnson (JNJ) and Medtronic (MDT), face potential headwinds. The trend also impacts healthcare providers like Hospital Corp. (HCA), which may see a shift in revenue from high-margin surgical procedures to outpatient drug administration services.
The rapid adoption of GLP-1 drugs is structurally reducing demand for bariatric surgery, forcing a sector-wide realignment in healthcare investment.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
AiX is our free MetaTrader 4 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. XAUUSD breakout engine.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.